NCT05049603View on ClinicalTrials.gov

A Randomized Clinical Trial to Evaluate the Effects of Atorvastatin on Graves' Orbitopathy (GO): the STAGO-2 Study

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

102

Participants

Timeline

Start Date

January 1, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions
Graves' Orbitopathy
Interventions
DRUG

Atorvastatin 20mg

One tablet/day, given approximately at 10 pm, after dinner and before going to bed, for 24 weeks

OTHER

Placebo

One tablet/day, given approximately at 10 pm, after dinner and before going to bed, for 24 weeks

Trial Locations (1)

56124

Ospedale Cisanello-Endocrinology II, Pisa

All Listed Sponsors
collaborator

Università degli Studi dell'Insubria

OTHER

collaborator

University of Catania

OTHER

collaborator

University of Messina

OTHER

lead

University of Pisa

OTHER